Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL
4/30/2013 11:42:25 AM
More...
|
Intercept Pharmaceuticals to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 18
3/12/2013 11:31:38 AM
More...
|
Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer
3/4/2013 11:25:05 AM
More...
|
Intercept Pharmaceuticals Announces Initiation of Phase 2 NASH Trial of OCA in Japan
1/8/2013 9:10:03 AM
More...
|
Intercept Pharmaceuticals Announces Completion of Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial
12/19/2012 9:13:20 AM
More...
|
Intercept Pharmaceuticals Announces Completion of Enrollment in FLINT
11/12/2012 7:47:03 AM
More...
|
Intercept Pharmaceuticals to Present Phase 2a Portal Hypertension Data at American Association for Study of Liver Diseases's Liver Meeting
11/9/2012 10:15:55 AM
More...
|
Intercept Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
10/15/2012 9:41:50 AM
More...
|
Intercept Pharmaceuticals, Kythera Biopharmaceuticals Take Off in IPOs
10/12/2012 10:28:52 AM
More...
|
Intercept Pharmaceuticals Announces Pricing of Initial Public Offering
10/11/2012 6:59:19 AM
More...
|
|